Please assess the completion status of the following clinical trial:

Trial Title: Haloperidol for Delirium in Adult Critically Ill Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria for randomisation:~1. Delirium, as assessed with the Intensive Care Delirium Screening Checklist - ICDSC: ≥4 or Confusion Assessment Method for the ICU - CAM-ICU: positive). NB Delirium can occur in the course of ICU admission or be present at admission.~2. Written Informed Consent is obtained from patient or legal representative~3. Complies with inclusion criteria but NOT exclusion criteria for eligibility:~Eligibility~Inclusion criteria for eligibility~1. Age ≥ 18 years~2. Admitted to ICU.~Exclusion criteria for eligibility~1. Admitted to ICU with a neurological diagnosis (such as acute stroke, traumatic brain injury, intracranial malignancy, anoxic coma). Previous non-acute stroke or other previous neurological condition without cognitive deterioration is not an exclusion criterion.~2. Pregnancy (to be excluded by pregnancy test in women of child baring age)~3. History of ventricular arrhythmia including torsade de pointes (TdP)~4. Known allergy to haloperidol~5. History of dementia or an Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) score ≥ 4~6. History of malignant neuroleptic syndrome or parkinsonism (either Parkinson's disease or another hypokinetic rigid syndrome)~7. Schizophrenia or other psychotic disorder~8. Inability to conduct valid delirium screening assessment (e.g. coma, deaf, blind) or inability to speak Dutch~9. The patient is expected to die within 24 hours, or is expected to leave the ICU within 24 hours after evaluation (may be reassessed daily)~Exclusion Criteria for randomisation:~1. Prolonged QT-interval (QTc \> 500ms)~2. (recent) torsade de pointes (TdP)~3. (recent) malignant neuroleptic syndrome or parkinsonism~4. Evidence of acute alcohol (or substance) withdrawal requiring pharmacological intervention (e.g. benzodiazepines or alfa-2 agonist) to treat~5. IQCODE not assessed~6. The patient is expected to die within 24 hours, or is expected to leave the ICU within 24 hours.~7. No (previously) signed informed consent by patient or representative~8. Current participation in another intervention trial that is evaluating a medication, device or behavioural intervention

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- haloperidol (Type: ACTIVE_COMPARATOR): study drug will be titrated based on delirium, diagnosed with a validated screening instrument (CAM-ICU or ICDSC), starting with 2.5mg IV q8h and titrated to a maximum of 5mg IV q8h.~Agitation and hallucinations will be managed according to a pre-specified protocol in both treatment arms. First the study drug will be increased when agitation or delirium remain present. Further options include mainly the use of alfa-2 agonists (agitation) or atypical antipsychotic drugs (hallucinations).
- placebo (Type: PLACEBO_COMPARATOR): study drug will be titrated based on delirium, diagnosed with a validated screening instrument (CAM-ICU or ICDSC), starting with 2.5mg IV q8h and titrated to a maximum of 5mg IV q8h.~Agitation and hallucinations will be managed according to a pre-specified protocol in both treatment arms. First the study drug will be increased when agitation or delirium remain present. Further options include mainly the use of alfa-2 agonists (agitation) or atypical antipsychotic drugs (hallucinations).

Based on this trial design, predict the completion outcome and termination type (if applicable).